SCHEMBL7746290

SCHEMBL7746290

N[C@@H](CO)C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
PTGS2 P35354 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PTGS1 P23219 1/20 0.42
GSTK1 Q9Y2Q3 1/20 0.42
ECE1 P42892 1/20 0.38
MME P08473 5/20 0.37
ACE P12821 2/20 0.37
CPA1 P15085 1/20 0.37
ACE2 Q9BYF1 1/20 0.37
GLO1 Q04760 1/20 0.37
PTPN1 P18031 1/20 0.37
ITGB1 P05556 1/20 0.35
ITGA5 P08648 1/20 0.35
FUCA1 P04066 1/20 0.33
FAAH O00519 1/20 0.33
HPGD P15428 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5173963 1.00 ALDH1A1 (0.42) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL10791497 1.00 ALDH1A1 (0.42) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL29386171 1.00 ALDH1A1 (0.42) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL5173973 1.00 ALDH1A1 (0.42) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL29385408 1.00 ALDH1A1 (0.42) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL29385929 1.00 ALDH1A1 (0.42) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL29385198 1.00 ALDH1A1 (0.42) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL10791516 1.00 ALDH1A1 (0.42) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL8070171 0.92 ALDH1A1 (0.48) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL8070167 0.92 ALDH1A1 (0.48) ALDH1A1LMNAMAPTPTGS2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1127117-A1 OPG FUSION PROTEIN COMPOSITIONS AND METHODS Amgen Inc., (US) 2001-08-29 EP claimed
WO-2001018203-A1 OPG FUSION PROTEIN COMPOSITIONS AND METHODS AMGEN INC. (US) 2001-03-15 WO claimed
WO-2025109783-A1 METHOD FOR ANALYZING ANTIBODY 中外製薬株式会社 2025-05-30 WO disclosed
WO-2025070337-A1 ANTI-MERTK AGONIST ANTIBODY, ANTI-MERTK BISPECIFIC ANTIBODY, AND USE THEREOF アステラス製薬株式会社 2025-04-03 WO disclosed
WO-2024111657-A1 METHOD FOR PRODUCING PROTEIN 中外製薬株式会社 2024-05-30 WO disclosed
WO-2024085166-A1 USE OF ANTI-CLDN4-ANTI-CD137 BISPECIFIC ANTIBODY COMBINED WITH PD-1 SIGNAL INHIBITOR FOR CANCER TREATMENT アステラス製薬株式会社 2024-04-25 WO disclosed
CN-114585651-A Novel antigen binding molecular forms 再生元制药公司 2022-06-03 CN disclosed
EP-1140136-A2 COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF CANCER AND BONE LOSS ASSOCIATED WITH CANCER Amgen Inc. (US) 2001-10-10 EP disclosed
EP-1127117-A1 OPG FUSION PROTEIN COMPOSITIONS AND METHODS Amgen Inc., (US) 2001-08-29 EP disclosed
WO-2001017543-A2 COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF CANCER AND BONE LOSS ASSOCIATED WITH CANCER AMGEN INC. (US) 2001-03-15 WO disclosed
WO-2001018203-A1 OPG FUSION PROTEIN COMPOSITIONS AND METHODS AMGEN INC. (US) 2001-03-15 WO disclosed